论文部分内容阅读
手术是治疗原发性甲状旁腺机能亢进的常用方法。作者在体外研究了类似钙的药物（R－568）抑制原发性甲状分腺机能亢进患者分泌甲状旁腺激素，从而降低血清甲状分腺激素和钙浓度的能力。作者将20个患轻度原发性甲状旁腺机能亢进的绝经后妇女随机地分为安慰组和实验组，实验组口服4～160mg钙受体激动剂R－568。在服用每个剂量后，重复测定血清甲状旁腺激素和钙浓度，并评价药物的安全性。实验结果表明R－568能剂量依赖性地抑制甲状旁腺激素的分泌。在基础水平，平均血清钙浓度是2．67±0．05mmol／L，平均血清甲状分腺激亲的浓度是77±11ng／L（18.8±2．7μmol／L），正常范围是16～65ng／L（3．9－15．9μmol／L），用20mgR－568后血清甲状分腺激素浓度降低26±8％（P=0．03），用80mgR－568后降低42±7％（p=0.01），用160mgR－568后降低51±5％（P=0．005）。只有在用160mgR－568后血清离子钙浓度才降低，其降低紧接着血清甲状旁腺激亲浓度降低出现。因此，研究结果表明类似钙的药物R－568能降低有原发性甲状旁腺机能亢进的约经后妇女的血清甲状旁腺激素浓度和离子钙浓度，该药物可用于治疗甲状旁除机能亢进，尤其可用于那些有手术禁忌征患者。这些药物也可用于慢性肾衰引起的继发性甲状务腺机能亢进?
Surgery is the common treatment for primary hyperparathyroidism. The authors investigated the ability of a calcium-like drug (R-568) to inhibit the secretion of parathyroid hormone in patients with primary hypothyroidism and thereby reduce serum thyroid hormone and calcium concentrations in vitro. The authors randomized 20 postmenopausal women with mild primary hyperparathyroidism to the placebo group and the experimental group, and the experimental group orally received 4 to 160 mg of the calcium receptor agonist R-568. After taking each dose, serum parathyroid hormone and calcium concentrations were repeatedly measured, and drug safety was evaluated. The experimental results show that R-568 can inhibit parathyroid hormone secretion in a dose-dependent manner. At the basal level, the mean serum calcium concentration was 2.67 ± 0.05 mmol / L, mean serum thyroid gland stimulant concentration was 77 ± 11 ng / L (18.8 ± 2.7 μmol / L), and the normal range was 16-65 ng /L(3.9-15.9|Ìmol/L). Serum levels of thyroid hormone decreased by 26 ± 8% (P = 0.03) with 20 mg of R-568 and decreased by 42 ± 7% with 80 mg of R-568 = 0.01), a decrease of 51 ± 5% after 160 mg R-568 (P = 0.005). Serum ionized calcium concentrations decreased only after 160 mg of R-568, with a decrease occurring immediately after the decrease in serum parathyroid concentration. Thus, the results of the study indicate that the calcium-like drug R-568 reduces serum parathyroid hormone levels and ionized calcium concentrations in postmenopausal women with primary hyperparathyroidism and is useful in the treatment of hypothyroidism , Especially for those who have surgical contraindications. These drugs can also be used for chronic renal failure caused by secondary thyroid hyperthyroidism?